Wutah pendapatan taun lumaku: Coeptis Therapeutics (COEP)

Logo perusahaan publik coeptistx.com (COEP)

Managing an early-stage micro-cap biotech requires verifying management's competence in attracting partners. The relative sales growth over a 12-month period compared to last year illustrates demand dynamics, while 0.00 records a new level. Coeptis Therapeutics (COEP) relies on the development of an NK-cell platform for blood cancer therapy, utilizing modernized laboratories for the analysis of oncohematological samples.

Wutah dodolan YoY sajrone rolas wulan kepungkur Coeptis Therapeutics Inc. (COEP): kanggo periode 11.02.2024 - 09.05.2026

coeptistx.com (COEP) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:COEP Coeptis Therapeutics Inc.
Sampel barang Coeptis Therapeutics

The effectiveness of Coeptis Therapeutics (COEP) cell therapy implementation is directly reflected in the relative revenue growth dynamics over the last four quarters compared to last year. This indicator measures the percentage change in sales volume over the past twelve months relative to the same period last year. The positive trend confirms the successful commercial scaling of innovative blood cancer treatment methods. However, sharp spikes may signal a decline in margins due to high costs. The stability of this metric determines the fundamental resilience of the business.